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Summary
Niemann-Pick type C (NPC) disease is an autosomal
recessive lipid-storage disorder usually characterized by
hepatosplenomegaly and severe progressive neurological
dysfunction, resulting from mutations affecting either
the NPC1 gene (in 95% of the patients) or the yet-to-
be-identifiedNPC2 gene. Our initial study of 25 patients
with NPC1 identified a T3182rC transition that leads to
an I1061T substitution in three patients. The mutation,
located in exon 21, affects a putative transmembrane
domain of the protein. PCR-based tests with genomic
DNA were used to survey 115 unrelated patients from
around the world with all known clinical and biochem-
ical phenotypes of the disease. The I1061T allele con-
stituted 33 (14.3%) of the 230 disease-causing alleles
and was never found in controls (1200 alleles). The mu-
tation was particularly frequent in patients with NPC
from Western Europe, especially France (11/62 alleles)
and the United Kingdom (9/32 alleles), and in Hispanic
patients whose roots were in the Upper Rio Grande val-
ley of the United States. The I1061Tmutation originated
in Europe and the high frequency in northern Rio
Grande Hispanics results from a founder effect. All seven
unrelated patients who were homozygous for the mu-
tation and their seven affected siblings had a juvenile-
onset neurological disease and severe alterations of in-
tracellular LDL-cholesterol processing. The mutation
was not found (0/40 alleles) in patients with the severe
infantile neurological form of the disease. Testing for
this mutation therefore has important implications for
genetic counseling of families affected by NPC.
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Introduction
Niemann-Pick type C (NPC) disease (MIM 257220) is
an autosomal recessive lipid-storage disorder usually
characterized by hepatosplenomegaly and severe pro-
gressive neurological dysfunction. In cultured cells, ly-
sosomal sequestration of endocytosed LDL-derived cho-
lesterol and accompanying anomalies in intracellular
sterol trafficking constitute the hallmark phenotypic fea-
tures of the disease and are used to assist in the diagnosis
of patients. In tissues, the pattern of accumulating lipids
is more complex and differs between brain and non-
neural organs. Marked variations have been observed in
the severity of the clinical course and in the cholesterol
processing abnormalities, and these define the clinical
and biochemical phenotypes, respectively (for review, see
Pentchev et al. 1995; Vanier and Suzuki 1996, 1998).
A genetic heterogeneity (NPC1 and NPC2) was estab-
lished by cell-hybridization and linkage studies (Stein-
berg et al. 1994; Vanier et al. 1996). The NPC1 gene
(mutated in ∼95% of patients) was mapped to 18q11
and was isolated by positional cloning (Carstea et al.
1997). The genomic structure was reported while this
manuscript was undergoing editorial review (Morris et
al. 1999). The cDNA sequence predicts a 1,278-amino-
acid protein with 16 transmembrane regions and a pu-
tative sterol-sensing domain (Carstea et al. 1997; Lange
and Steck 1998). The protein appears to be located in
the late endosomal membranes (Kobayashi et al. 1999;
Neufeld et al. 1999) but also seems to interact with
lysosomes (Neufeld et al. 1999). Deletion of the four
amino acid residues containing the lysosome-targeting
motif has been shown to result in the retention of the
protein in the endoplasmic reticulum (Watari et al.
1999). Apart from the eight mutations reported together
with positional cloning of the gene (Carstea et al. 1997),
only the mutation found in the Nova Scotian patients
(previously designated as type D) has been published
(Greer et al. 1998). Initial studies in the laboratories of
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the authors (Yamamoto et al. 1999; G. Millat and M.
T. Vanier, unpublished data; J. A. Morris and P. G.
Pentchev, unpublished data) disclosed a very large mu-
tational spectrum in patients with NPC1. While nearly
all mutations appeared to be private, there was an in-
dication that one particular missense mutation, I1061T,
might be frequent, although not in Japanese.
A survey including 115 unrelated patients, covering
all known clinical and biochemical phenotypes of the
disease, was therefore undertaken, after simple tests on
genomic DNA were devised. The largest proportion of
patients originated from Western Europe. Remaining pa-
tients were from a much wider geographic area—more
specifically, North Africa, the Middle East, French Can-
ada, and the isolate of Hispanic Americans from north-
ern Colorado described by Wenger et al. (1977). For
each patient, the absence or presence of one or two mu-
tant alleles was compared to the clinical subtype and to
the severity of alterations of intracellular LDL-choles-
terol trafficking to establish genotype/phenotype cor-
relations.
Subjects and Methods
Subjects
Cultured skin fibroblasts or peripheral blood samples
were obtained from 120 patients with NPC who be-
longed to 115 unrelated families and from the parents
in 8 of these families. The geographic or ethnic origin
of the families was as follows: France, 31; United King-
dom, 16; Germany, 13; Belgium, 5; Switzerland, 6; Italy,
9; Poland, 1; Czechoslovakia, 3; North Africa, 6; Spain,
3; Portugal, 1; Greece, 2; Turkey, 2; Yugoslavia, 2;
Gypsy, 1; Arab Emirates, 2; Costa Rica, 2; Lebanon, 1;
Pakistani, 1; Australia, 1; French Canada, 3; and His-
panics from the Northern Rio Grande valley of the
United States, 4. The diagnosis was finally assessed on
fibroblast cultures by demonstration of intralysosomal
storage of unesterified cholesterol by filipin staining and
study of LDL-induced cholesterol esterification (Vanier
et al. 1991b). Cells from all patients were evaluated or
reevaluated in a single laboratory (Lyon). In 51 families,
genetic complementation analysis (Vanier et al. 1996)
had been performed to assess that the patient did belong
to the main complementation group (mutation in the
NPC1 gene). Classification of patients into various clin-
ical phenotypes was done as previously proposed by us
(Vanier et al. 1988, 1991a; Vanier and Suzuki 1996).
Neurological patients were categorized by type and age
at onset of first neurological symptoms into either a se-
vere infantile form (onset at age !2 years), a late infantile
form (onset at age 3–5 years), a juvenile form (onset at
age 5–16 years), or an adult form (onset at age 116
years). The denomination “rapidly fatal cholestatic
form” applied to patients who died from liver failure in
the first months of life. Our criteria for inclusion of pa-
tients into three biochemical phenotypes, on the basis of
the severity of impairment in intracellular cholesterol
processing in cultured fibroblasts, have also been well
documented (Vanier et al. 1991b). The classic phenotype
includes patients with a striking accumulation of free
cholesterol in lysosomes, as assessed by filipin staining,
together with a severe block in LDL-induced cholesteryl
ester formation, studied after a 4.5-h challenge with LDL
(!100 pmol cholesteryl ester formed, compared to a nor-
mal value of 2,950  1,200). Cells from “variant” pa-
tients show only mild changes (filipin stain may be pos-
itive only after challenge with pure LDL, with cholesteryl
ester formation ranging from 500 pmol to normal). Ge-
nomic DNA was further obtained from a control pop-
ulation of 100 unrelated unaffected subjects.
RNA isolation and cDNA reverse transcription.—Total
RNA was isolated from fibroblast monolayers by the
Trizol reagent (Gibco BRL, Life Technologies), and re-
verse transcription was performed using the First-Strand
cDNA Synthesis kit (Amersham Pharmacia Biotech), ac-
cording to the manufacturers’ instructions.
SSCP and sequencing.—The NPC1 cDNA was am-
plified in 18 overlapping fragments. Each PCR was per-
formed in a 20-ml reaction volume containing 0.4 ml of
cDNA, 200 mM each dNTP, 1.5 mM MgCl2, PCR buffer,
1 U of EurobioTaq, 4 pmol each primer, and 0.1 ml
a[33P]dATP, 3000 Ci/mmol (Amersham Pharmacia Bio-
tech). Two microliters of the radiolabeled PCR product
was mixed with 15 ml stop solution (95% formamide,
10 mM NaOH, 0.25% bromphenol blue, 0.25% xylene
cyanol) and was denatured for 5 min at 95C. The sam-
ples were loaded on 0.5# mutation detection enhance-
ment gels (FMC BioProducts) with or without 10% glyc-
erol. Electrophoresis was run in 0.6# Tris-borate EDTA
running buffer either at 20 W at 4C or at 6 W at
room temperature.
For sequencing, PCR was performed on cDNA with
primers Os and Oas and on genomic DNA with primers
F10 and Oas (table 1). After amplification, PCR prod-
ucts were purified and were directly sequenced on Se-
quagel-6 gels (National Diagnostics) by use of the Ther-
mosequenase cycle sequencing kit with the forward
exonic primer GM1s labeled with g[33P]-ATP, 3000 Ci/
mmol) (Amersham Pharmacia Biotech).
Allele-Specific Oligonucleotide (ASO) Analysis
Genomic DNA was PCR-amplified using primers F10
(sense) and Oas (antisense) (table 1). The 35 PCR cycles
each included 1 min at 94C, 1 min at 60C, and 2 min
at 72C. The ∼3-kb PCR product was laid as dot-blot
on a nylon membrane (Hybond-N, Amersham Phar-
macia Biotech). Membranes were prehybridized for 1 h
at 65C in 3M trimethylacetate buffer containing 10 mM
NaHPO4, 0.5 M EDTA, 10% SDS, 1% Denhardt, and
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Table 1
Oligonucleotide Sequences
Oligonucleotide
cDNA
Coordinatesa Sequence (5′r3′)
Os 3028/3049 AAGTGTGGCAAAGGGGGACATG
Oas 3309/3286 ACCGAGGTTGAAGATAGTGTCGTC
F10 2949/2967 TCCGGAAGGCAAACAGAGG
GM1s 3043/3062 GGACATGCTGCCTATAGTTC
RS-1061sb 3156/3181 TGACGCTCTGAAGAAAGCCCGACGTA
RS-1061as tcccacccagtgtaggccctttgctg
ASO-I1061I 3191/3172 TTACTGGCTATAAGTCGGGC
ASO-I1061T 3172/3191 GCCCGACTTACAGCCAGTAA
NOTE.—Exonic sequences are given in uppercase and intronic se-
quences in lowercase characters.
a Counted from the adenosine residue of the initiation codon.
b The underlined nucleotide generates a Rsa I site when mutation
I1061T is present.
Figure 1 Sequence of NPC1 exon 21 with intron boundaries,
depicting the location of the T3182rC transition and the design of
primers for detection of the mutation by creation of a Rsa I restriction
site. Intronic sequences are in lowercase characters; exonic sequences
are in uppercase.The asterisk (*) indicates the base change made in
the forward primer to introduce a RsaI restriction site when the ad-
jacent TrC base change is present.
100 mg salmon sperm DNA/ml. Digoxigenin-labeled
wild-type (ASO-I1061I) or mutated (ASO-I1061T)
probes (10 pM) (table 1) were added to the prehybri-
dization solution, and hybridization was conducted for
1 h at 65C. Membranes were washed first for 2 min at
room temperature in 1% SSC, 10% SDS, then for 2 min
at 65C in 50 mM Tris-HCl pH 7.5, 3M trimethylace-
tate, 2 mM EDTA, and 0.1% SDS. The hybridized prod-
ucts were visualized by use of a digoxigenin luminescent
detection kit (Roche Diagnostics).
Mutation Detection by Introduction of an Rsa I
Restriction Site
Genomic DNA was PCR-amplified using the primers
RS-1061s and RS-1061as (table 1). The 30 PCR cycles
each included steps of 30 s at 92C for denaturation, at
56C for annealing, and at 72C for extension. The 147-
bp PCR product was digested for 2 h at 37C by Rsa I
and was analyzed on a 3% Metaphor gel (FMC Bio-
Products).
Results
A T3182rC Transition Leading to an I1061T Substitution
Is a Frequent Mutation in Patients with NPC1
In the process of a complete mutational analysis in
25 NPC1 patients covering the entire spectrum of clinical
phenotypes, 3 patients with a neurological juvenile clin-
ical presentation studied by sequencing of cDNA and
genomic DNA were found to have a T3182rC transition
leading to a I1061T substitution. This hydrophobic/hy-
drophilic amino acid change was located within one of
the putative transmembrane domains (Carstea et al.
1997) of the protein. The mutant allele was present in
the heterozygous state in one French patient (15.1) (table
4) and in one Hispanic patient (20.1) from northern
Colorado (table 4). The homozygous status of another
French patient (1.3) (table 3) was definitively assessed
from parental studies. Since all other mutations identi-
fied appeared to be private, a wider screening for the
I1061T allele was performed. Because no information
was initially available regarding the genomic structure
of NPC1, allele-specific oligonucleotide analysis was first
chosen to screen a larger population of patients of Eu-
ropean descent as well as a normal population. The in-
itial data were confirmed, and the study of 90 additional
patients indicated that I1061T was a frequent mutation
in this population. Meanwhile, the intronic sequences
flanking the responsible exon, further characterized as
exon 21 (Morris et al. 1999; T. Yamamoto and E.
Nanba, unpublished data), were determined (fig. 1). An
alternative procedure was then devised, by introduction
of an Rsa I restriction site by means of a sense primer
with a G mismatch at the 3′ terminus combined with an
intronic antisense primer (table 1). While the normal
allele remains uncut (147 bp), the mutant allele appears
as a shorter 122-bp band (fig. 2). Combining the results
obtained by one method or the other, 115 unrelated
patients with NPC (table 2), 16 parents (from families
1, 3, 4, 8, 9, 20, 22, 24) (see table 3 and table 4) and
100 control subjects (data not shown) were studied in
total. The I1061T allele was never found in the control
population and constituted 33/230 alleles (14.3%) in the
global NPC population.
Analysis of the NPC Population
Genotype/phenotype correlations.—The data pre-
sented in table 2 give two clear indications. First, the
I1061T allele is predominantly found in patients with
the most typical NPC presentation—that is, with a ju-
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Figure 2 Restriction analysis of the I1061T mutation in a rep-
resentative family. In presence of the mutation, Rsa I digestion of the
147-bp PCR product generates a 122-bp fragment. The results pre-
sented are those in family 1 (see table 3). Mk indicates molecular-mass
DNA marker (100 and 200 bp); Fa, father; Mo, mother; P1, P2, P3,
P4, affected siblings; Contr, normal subject. The plus sign () denotes
the presence of a I1061T allele; the minus sign () denotes its absence.
venile neurological onset and pronounced abnormalities
of intracellular LDL-cholesterol processing (the classic
biochemical phenotype). In this population, I1061T con-
stituted 30% (25/84) of alleles, and all seven homoallelic
patients were included in that group. Second, this mu-
tation was never found in patients with the severe in-
fantile neurological form of the disease (0/40 alleles). On
the other hand, a heteroallelic status could be associated
either with a slightly more aggressive disease (neurolog-
ical late infantile form, 2/12 patients), or with an adult
neurological (1/8 patients) or nonneurological (2/4 pa-
tients) form.
In five of the seven families with homoallelic patients,
several siblings were affected, and the clinical history of
a total of 15 patients is reported in table 3. The median
age of onset of neurological symptoms was relatively
late, ∼10 years, with learning problems at school as the
major first complaint. Later symptoms included cere-
bellar signs, especially problems with fine hand move-
ments, ataxia, dystonia, and vertical supranuclear
ophthalmoplegia. The course of the disease was, in gen-
eral, quite slow. Two patients died at age 16 years, but
three survived until ages 28.5, 34, and 39 years. Several
others were still alive at age 20 years.
The clinical pattern of patients who were heteroallelic
for the I1061T mutation was much wider, as would be
expected for compound heterozygotes. In 12/20 families,
patients belonged to the neurological juvenile form and
showed classic biochemical alterations. Patients in two
additional families were still very young, so their neu-
rological course could not be predicted. It should also
be noted that the rapidly fatal cholestatic form of the
disease is not correlated with the nature of the NPC1
mutation, since it has often been found to be associated
with neurological forms in the same sibship (Vanier et
al. 1991a). Interestingly, the mutation was also found
in three adults—one with a neurological disease and two
with isolated splenomegaly. In patient 27.1, the diag-
nosis had been primarily assessed in the study of splenic
lipids (Dr. K. Harzer, Tu¨bingen, Germany). Finally,
although the I1061T mutation was clearly associated
with a “classic” biochemical pattern, a “variant” pattern
(milder alterations) occurred in heterozygotes with
about the same frequency as is generally observed in a
large population of patients.
Geographic distribution of the patients carrying the
mutation.—A striking observation was the fact that pa-
tients in three of the four Hispanic American families
from the Northern Rio Grande area (families 5, 6, and
7) (table 3) were homozygotes for the mutation. A het-
erozygote status (patient 20.1) in the fourth family (table
4) could probably be explained by mixed Italian ances-
try. Nevertheless, the study of a large European popu-
lation (table 3 and table 4) disclosed that this mutation
was also quite prevalent among patients with NPC orig-
inating from France (11/62 alleles), the United Kingdom
(9/32 alleles), and, to a lesser extent, Switzerland and
Germany (4/38 alleles). From our current data, the mu-
tation would appear less frequent in other European
countries (Italy, Spain, Portugal, Greece, Belgium), but
the number of families studied is too small for a definitive
conclusion. A homozygote family was also observed in
French Canadians from Quebec, and a heterozygote was
found in an Australian family with an English name.
Taken together, the data suggest that the I1061T mu-
tation originated in Europe and is found in the Hispanics
of the northern Rio Grande due to a founder effect.
Discussion
Our data demonstrate that an I1061T substitution in
the NPC1 gene is a frequent mutant allele in patients
with NPC who have a European background. It was
important to ascertain that I1061T is a disease-causing
mutation, since unpublished work from our laboratories
has given evidence that, in this gene, several common
polymorphisms are present, both in patients and in the
general population. Interestingly, four of those poly-
morphisms (H215R, I858V, N931N, and R1266Q) are
shared by Europeans and Japanese (Yamamoto et al.
1999; G. Millat and M. T. Vanier, unpublished data). In
the absence of a straightforward way to perform ex-
pression studies of NPC1, screening of a large control
population on genomic DNA provided good evidence
that I1061T was a disease-related mutation. The fact
that patients homozygous for the mutation share a very
homogeneous clinical and biochemical phenotype was
another strong argument. In the three families in which
parents could also be studied, both were confirmed to
carry the mutation, excluding the possibility of a second
allele with a large deletion in the patients.
Since I1061T appeared as a potentially frequent
NPC1 mutation, our next aim was to investigate
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Table 2
Study of the I1061T Mutation in a Population of 115 Unrelated NPC Patients Covering the Various Clinical and
Biochemical Phenotypes of the Disease
CLINICAL PHENOTYPE
BIOCHEMICAL
PHENOTYPE
NO. OF PATIENTS
WITH I1061T MUTATION STATUS
Homoallelic Heteroallelic Not Found
Neurological onset ( ):n = 96
Infantile ( )n = 20 Classic ( )n = 20 0 0 20
Late infantile ( )n = 12 Classic ( )n = 12 0 2 10
Juvenile ( )n = 56 Classic ( )n = 42 7 11 24
Intermediate ( )n = 6 0 0 6
Variant ( )n = 8 0 1 7
Adult ( )n = 8 Classic ( )n = 3 0 0 3
Variant ( )n = 5 0 1 4
No neurological disease ( ):n = 19
Cholestatic rapidly fatal (age !1 year) ( )n = 3 Classic ( )n = 3 0 1 2
Children age !6 years (short follow-up) ( )n = 12 Classic ( )n = 10 0 2 8
Variant ( )n = 2 0 0 2
Adults ( )n = 4 Classic ( )n = 1 0 1 0
Variant ( )n = 3 0 1 2
whether clear genotype/phenotypes correlations could be
established. Therefore, it was essential to screen a pop-
ulation of patients fully representative of the various
clinical and biochemical phenotypes described in our
earlier large surveys (Vanier et al. 1988, 1991a, 1991b).
Regarding clinical aspects, a majority of patients with
NPC have a neurological disease with a juvenile or late
infantile onset; these phenotypes cover 60% of the pa-
tients in the present study. However, in Europe, the Mid-
dle East, and North Africa, patients with the severe in-
fantile neurological form were found to represent
20%–30% of the patients in an earlier study (Vanier et
al. 1991a). Such patients clinically differ from the other
forms, and we felt that it was important to include them
in a proportion similar to that previously reported by
us. As predicted, more adult patients have been diag-
nosed with NPC in recent years (Patterson et al. 1999).
Unexpectedly, some of them did not present neurological
abnormalities (Vanier and Suzuki 1998; Fensom et al.
1999), and molecular-level studies of such atypical pa-
tients are particularly important. The question of symp-
tomatic heterozygotes could have been raised in the two
patients with isolated splenomegaly and mild alterations
of cellular cholesterol metabolism (Vanier and Suzuki
1998), if not for a pathognomonic profile of splenic lip-
ids (studied by Dr. K. Harzer, Tu¨bingen). Finally, three
patients who had died from the neonatal, rapidly fatal
cholestatic form were included, although there is good
evidence from familial and molecular genetics studies
that the perinatal liver disease does not correlate with
the mutation (Vanier et al. 1991a; Vanier and Suzuki
1998; G. Millat and M. T. Vanier, unpublished data).
Regarding the severity of alterations in intracellular
LDL-cholesterol processing, we and others (Vanier et al.
1988; 1991b; Bowler et al. 1990) have documented a
wide range of variation, with only partial correlation to
clinical course (Vanier and Suzuki 1998). Of the patients
included in the present study, ∼20% showed a “variant”
or “intermediate” biochemical phenotype, a proportion
quite similar to that published earlier by us in a random
population (Vanier et al. 1991b).
Compared to the course of the disease in a large survey
of patients (Vanier et al. 1988), there was a clear trend
for the 15 homozygous I1061T patients to show a quite
homogeneous phenotype, with late and insidious onset
of the neurological disease. Several patients previously
reported in the literature (Wenger et al. 1977; Pons et
al. 1976) showed only learning problems in school and
mental retardation for a long period. The later course
of the disease, although typical for NPC (cerebellar in-
volvement, dystonia, vertical supranuclear ophthalmo-
plegia), was, in general, slowly progressive. Several pa-
tients survived in their twenties or even their thirties.
This mutation thus appears correlated with a relatively
mild neurological phenotype with juvenile onset. Inter-
estingly, it might exclude the most aggressive infantile
neurological form, since no copy of this mutant allele
was found in 20 such patients. On the other hand, the
I1061T mutation was present in one allele of two pa-
tients with a neurological late infantile form and of two
adult patients with isolated splenomegaly and no neu-
rological disease (Vanier and Suzuki 1998; Fensom et al.
1999). Identification of the other mutation in these pa-
tients appears to be critical for better understanding of
the genotype/phenotype correlations and is currently un-
der way. It is obvious that the I1061T substitution leads
to a severe disruption of cellular LDL-cholesterol pro-
cessing. The nature and location of the associated mu-
tations may shed light on the mechanism that differ-
entiates severe (classic) and mild (variant) cellular
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Table 4
Origin and Phenotypes of 23 Patients with NPC (20 Families) Heteroallelic for the I1061T Mutation
Patient
Identificationa Origin Clinical Phenotype
Biochemical
Phenotype
Age at
Death
Age at Last
Follow-Up
(years)
8.1b France N, Late infantile Classic 8 years
8.2 N, Late infantile Classic 10.5
9.1b United Kingdom N, Late infantile Classic 8 years
9.2 N, Late infantile Classic 10
10.1 France N, Juvenile Classic 7
11.1 France N, Juvenile Classic 11 years
12.1 France N, Juvenile Classic 7
13.1 France N, Juvenile Classic 10.5
14.1 France N, Juvenile Classic 10
15.1 France N, Juvenile Classic 32
16.1 United Kingdom N, Juvenile Classic 11
17.1 United Kingdom N, Juvenile Classic 25 years
18.1 United Kingdom N, Juvenile Classic 7
19.1 United Kingdom N, Juvenile Classic 12
20.1 United States, Hispanicc N, Juvenile Classic
21.1b United Kingdom N, Juvenile Variant 18 years
21.2 N, Juvenile Variant 21
22.1 United Kingdom N, Adult Variant 32
23.1b,d United Kingdom Cholestatic rapidly fatal form Classic 19 d
24.1 Australia Non-neurological Classic 1
25.1b Germany/Italy Non-neurological Classic 3
26.1e United Kingdom Non-neurological Classic 51
27.1 Germany Non-neurological Variant 53
NOTE.—N = neurological.
a The number before the dot indicates the family; the number after the dot indicates the individual patient.
b The parents of this patient were also studied, and one of them was found to be heterozygous.
c Hispanic from Northern Rio Grande with Italian grandmother.
d Patient 2, Maconochie et al. (1989).
e Fensom et al. (1999).
cholesterol alterations, which seems genetically deter-
mined (Vanier et al. 1991a).
Patients included in the study originated, to a large
extent, from Western Europe, most prominently from
France and the United Kingdom, but also from Belgium,
Germany, Switzerland, Italy, Spain, and Portugal. Ex-
cluding families with the neurological infantile pheno-
type in which the I1061T mutation is apparently never
present, our results indicate that in France (9/24) and in
the United Kingdom (9/14), the I1061T mutation is fre-
quent among families affected by NPC, with at least one
allele found in 40%–60% of the families. Although a
lesser frequency was observed in other European coun-
tries, one should be very careful not to overinterpret the
data, considering the smaller number of families tested.
The mutation was not observed in a study of 10 Japanese
patients but constituted one mutant allele of the
GM03123 cell line (Yamamoto et al. 1999). The hy-
pothesis that it probably originates from Western Europe
is strengthened by the observation that the mutation
occurs in countries with a strong historical European
immigration. We have indications that this applies to
Quebec and Australia and, definitely, to the United
States.
In the United States, we demonstrated that the I1061T
substitution is highly prevalent in Hispanic patients from
the Upper Rio Grande valley. Two additional patients
with roots in this region were recently diagnosed with
NPC, and both were homozygous for the mutation (D.
A. Wenger and M. A. Rafi, unpublished data). The only
two heterozygous patients (including 20.1) currently
known to be living in this area proved to have a non-
Hispanic parent or grandparent. The mutation is nat-
urally not limited to this population, and an additional
study of 26 U.S. patients with Anglo-Saxon or Asian
surnames showed that 7 carried one mutant allele (D.
A. Wenger and M. A. Rafi, unpublished). No copy of
the mutant allele was found in the four Hispanic patients
from California and Florida studied so far. Consistent
with our previous statement, no patient with one copy
of this mutation had a severe infantile phenotype.
Most of the families in the Upper Rio Grande valley
can trace their ancestors to Spanish settlers who came
up from Mexico in the late 17th and early 18th centuries.
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It seems obvious that one or more carriers of this mu-
tation were present in this group of settlers. A number
of Hispanic patients homozygous for this mutation re-
cently diagnosed in Colorado and New Mexico live in
the larger cities, such as Denver or Albuquerque. How-
ever, all have parents or grandparents originating from
the smaller towns between Santa Fe, New Mexico and
Alamosa, Colorado. The carrier rate in that population
may be as high as 1 in 30, similar to that of Tay-Sachs
disease (MIM 272800) in the Ashkenazi Jewish popu-
lation. A similar founder effect has previously been dem-
onstrated (Winsor and Welch 1978) in the Acadian pop-
ulation of Nova Scotia, Canada, where a different
common mutation, G992W, was identified (Greer et al.
1998). Screening programs to identify carriers in these
populations may be useful to those seeking genetic in-
formation. More generally, considering the frequency of
the I1061T substitution found in the present study, we
advocate testing all white patients with NPC for this
mutation, since every positive allele will allow reliable
heterozygote screening for family members with this
mutation.
The I1061T substitution, resulting from to a TrC
transition located in exon 21 of the NPC1 gene, affects
the predicted transmembrane domain 10 of NPC1 not
homologous to Patched1. Antibodies against NPC1,
now available in several laboratories, including ours,
should allow cytochemical and biochemical studies of
the mutated protein. Considering the very “classic” clin-
ical and biochemical phenotypes of patients homozygous
for the mutation, such studies may provide interesting
information for functional characterization of NPC1.
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